Literature DB >> 7569018

Prognostic factors in patients with cervix cancer treated by radiation therapy: results of a multiple regression analysis.

A W Fyles1, M Pintilie, P Kirkbride, W Levin, L A Manchul, G A Rawlings.   

Abstract

A retrospective analysis of 965 patients with invasive cervix cancer treated by radiation therapy between 1976 and 1981 was performed in order to evaluate prognostic factors for disease-free survival (DFS) and pelvic control. FIGO stage was the most powerful prognostic factor followed by radiation dose and treatment duration (P values = 0.0001). If the analysis was limited to patients treated with radical doses of 75 Gy or more, dose was no longer significant. Young age at diagnosis, non-squamous histology and transfusion during treatment were also adverse prognostic factors for survival and control. Para-aortic nodal involvement on lymphogram was associated with a reduction in DFS (P = 0.0027), whereas pelvic lymph node involvement alone was not. In patients with Stage I and IIA disease, tumour size was the most powerful prognostic factor for survival (P = 0.0001) and the extent of pelvic sidewall involvement was significant in patients with Stage III tumours (P = 0.007). Histological grade appeared to be a predictive factor but was only recorded in 712 patients. These features should be considered in the staging of patients and in the design of clinical trials.

Entities:  

Mesh:

Year:  1995        PMID: 7569018     DOI: 10.1016/0167-8140(95)01535-o

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  22 in total

1.  Compliance to the prescribed overall treatment time (OTT) of curative radiotherapy in normal clinical practice and impact on treatment duration of counteracting short interruptions by treating patients on Saturdays.

Authors:  M Maciá I Garau; J Solé Monné; M J Cambra Serés; C Monfà Binefa; M Peraire Llopis
Journal:  Clin Transl Oncol       Date:  2009-05       Impact factor: 3.405

2.  Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials.

Authors:  Bradley J Monk; Chunqiao Tian; Peter G Rose; Rachelle Lanciano
Journal:  Gynecol Oncol       Date:  2007-02-02       Impact factor: 5.482

Review 3.  Hypoxia and anaemia in patients with cancer of the uterine cervix.

Authors:  Francisco José Andreu-Martínez; Julia M Martínez-Mateu
Journal:  Clin Transl Oncol       Date:  2005-09       Impact factor: 3.405

Review 4.  DNA hypermethylation biomarkers to predict response to cisplatin treatment, radiotherapy or chemoradiation: the present state of art.

Authors:  Frank Roossink; Steven de Jong; G Bea A Wisman; Ate G J van der Zee; Ed Schuuring
Journal:  Cell Oncol (Dordr)       Date:  2012-07-27       Impact factor: 6.730

5.  Human papillomavirus genotype affects metastatic rate following radiotherapy in patients with uterine cervical cancer.

Authors:  Noriyuki Okonogi; Daijiro Kobayashi; Tomo Suga; Takashi Imai; Masaru Wakatsuki; Tatsuya Ohno; Shingo Kato; Takashi Nakano; Tadashi Kamada
Journal:  Oncol Lett       Date:  2017-11-02       Impact factor: 2.967

Review 6.  Different strategies of treatment for uterine cervical carcinoma stage IB2-IIB.

Authors:  Lucas Minig; María Guadalupe Patrono; Nuria Romero; Juan Francisco Rodríguez Moreno; Jesús Garcia-Donas
Journal:  World J Clin Oncol       Date:  2014-05-10

7.  The role of PET/CT in cervical cancer.

Authors:  Fernanda G Herrera; John O Prior
Journal:  Front Oncol       Date:  2013-02-26       Impact factor: 6.244

8.  A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer.

Authors:  Fady B Geara; Ali Shamseddine; Ali Khalil; Mirna Abboud; Maya Charafeddine; Muhieddine Seoud
Journal:  Radiat Oncol       Date:  2010-09-23       Impact factor: 3.481

9.  Sociodemographic factors and delay in the diagnosis of cervical cancer in Morocco.

Authors:  Mohamed Berraho; Majdouline Obtel; Karima Bendahhou; Ahmed Zidouh; Hassan Errihani; Abdellatif Benider; Chakib Nejjari
Journal:  Pan Afr Med J       Date:  2012-05-25

10.  Retrospective feasibility study of simultaneous integrated boost in cervical cancer using Tomotherapy: the impact of organ motion and tumor regression.

Authors:  Fernanda G Herrera; Sharon Callaway; Ela Delikgoz-Soykut; Mehtap Coskun; Laetitia Porta; Jean-Yves Meuwly; Joao Soares-Rodrigues; Leonie Heym; Raphael Moeckli; Mahmut Ozsahin
Journal:  Radiat Oncol       Date:  2013-01-03       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.